Virus Purification via Multi-Modal Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying viruses are limited in scalability and compliance with cGMP regulations, particularly for industrial-scale production of highly purified viruses and antigens, leading to challenges in vaccine creation and gene therapy applications.
Innovation Solution
A multi-set process involving virus harvesting, clarification, concentration using filtration, and subsequent separation procedures including ion-exchange chromatography and multi-modal chromatography to separate host cell contaminants and residual impurities, enabling commercial-scale production of highly purified viruses and antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional virus purification methods (crude cell lysate, ultracentrifugation) are used, then small biochemical quantities (nanograms to milligrams) can be obtained, but industrial-scale production (grams to kilograms) cannot be achieved
Solution Approach 1:
The purification process is divided into multiple sequential steps: initial clarification, concentration, ion-exchange chromatography, and multi-modal chromatography. Each step targets specific impurities and progressively increases purity while maintaining scalability from laboratory to industrial production levels.
Solution Approach 2:
The patent extracts and removes specific impurities at different stages: cellular debris is removed by clarification, proteins are removed by ion-exchange chromatography, and residual impurities are removed by multi-modal chromatography. This systematic extraction enables scaling from small to large quantities while maintaining purity.
2Manufacturing precision
If traditional purification methods are used, then crude virus preparations can be obtained quickly, but high purity compliant with cGMP regulations cannot be achieved
Solution Approach 1:
The purification process is segmented into distinct stages, each with specific functions: clarification removes debris, concentration increases virus density, ion-exchange chromatography removes proteins, and multi-modal chromatography removes residual impurities. This segmentation achieves cGMP compliance while organizing complexity into manageable steps.
Solution Approach 2:
The patent uses intermediate purification steps with specific resins and chromatography media as intermediaries to progressively purify the virus. Each intermediary targets specific types of impurities, enabling systematic removal of contaminants while maintaining virus integrity and achieving required purity levels.
3Loss of time
If crude cell lysate method is used, then rapid virus preparation is achieved, but contamination with non-virus factors (proteins, nucleic acids, lipids) prevents proper experimentation
Solution Approach 1:
The patent systematically extracts different types of contaminants at specific stages: cellular debris is extracted by clarification, proteins are extracted by ion-exchange chromatography, and residual impurities including nucleic acids and lipids are extracted by multi-modal chromatography. This enables rapid yet thorough purification.
Solution Approach 2:
Each purification step is optimized to remove specific types of impurities: clarification targets debris, ion-exchange targets proteins, and multi-modal chromatography targets residual contaminants. This localized approach to quality control efficiently removes harmful factors while minimizing processing time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high-purity virus and antigen production on a commercial scale, compliant with cGMP regulations, facilitating scalable and reproducible vaccine development and therapeutic applications.
Implementation Method 1
concentrating the separated and clarified virus with a filtration device with a membrane with pores of a size not to exceed a predetermined limit as selected by a user
Implementation Method 2
at least one separation procedure includes ion-exchange chromatography to separate host cell contaminants from the virus
Implementation Method 3
at least one separation procedure includes a multi-modal chromatography to separate residual impurities from the virus on the basis of at least size differences between the virus and the impurities, and chemical interaction occurring between the impurities and one or more chromatography ligands
Data Source
AI summary
Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.